A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma

BACKGROUND: Fibroblast growth factors (FGFs) have a fundamental role in cancer. Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small molecule inhibitors of FGFR, including hyperphosphatemia and retinal, nail, and skin toxi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: van Brummelen, Emilie M. J., Levchenko, Evgeny, Dómine, Manuel, Fennell, Dean A., Kindler, Hedy L., Viteri, Santiago, Gadgeel, Shirish, López, Pilar Garrido, Kostorov, Vladimir, Morgensztern, Daniel, Orlov, Sergey, Zauderer, Marjorie G., Vansteenkiste, Johan F., Baker-Neblett, Katherine, Vasquez, James, Wang, Xiaowei, Bellovin, David I., Schellens, Jan H. M., Yan, Li, Mitrica, Ionel, DeYoung, M. Phillip, Trigo, José
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6898757/
https://ncbi.nlm.nih.gov/pubmed/31065954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00783-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados